Ticker
ABUS

Price
2.95
Stock movement down
-0.08 (-2.64%)
Company name
Arbutus Biopharma Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
464.63M
Ent value
498.90M
Price/Sales
12.91
Price/Book
3.19
Div yield
-
Div growth
-
Growth years
-
FCF payout
0.06%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
2.43%
3 year return
27.00%
5 year return
-10.01%
10 year return
-4.11%
Last updated: 2023-03-22
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with this event.
March 7, 2023

iO Charts is a Seeking Alpha partner

Arbutus Biopharma Corporation (NASDAQ:NASDAQ:ABUS) Q4 2022 Earnings Conference Call March 2, 2023 8:45 AM ETCompany ParticipantsLisa Caperelli - VP of IRWilliam Collier - President and...
March 2, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABUS does not pay dividends or no data was received
Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
March 2, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
March 1, 2023

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF0.02
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales12.91
Price to Book3.19
EV to Sales13.87
Arbutus Biopharma has the potential to successfully develop and commercialize its drug candidates for treating chronic HBV infection. Click here to see why ABUS stock is a Hold.
February 23, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
November 9, 2022

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count157.50M
EPS (TTM)-0.46
FCF per share (TTM)136.30

Income statement

Loading...
Income statement data
Revenue (TTM)35.98M
Gross profit (TTM)35.98M
Operating income (TTM)-63.69M
Net income (TTM)-68.84M
EPS (TTM)-0.46
EPS (1y forward)-0.57

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-177.01%
Profit margin (TTM)-191.34%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash24.00M
Net receivables6.42M
Total current assets141.14M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets203.80M
Accounts payable12.27M
Short/Current long term debt2.31M
Total current liabilities27.51M
Total liabilities58.28M
Shareholder's equity145.52M
Net tangible assets145.52M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-17.35M
Capital expenditures (TTM)511.00K
Free cash flow (TTM)20.58B
Dividends paid (TTM)12.14M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-47.31%
Return on Assets-33.78%
Return on Invested Capital-47.19%
Cash Return on Invested Capital14108.18%
Arbutus Biopharma Corporation (NASDAQ:NASDAQ:ABUS) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ETCompany ParticipantsLisa Caperelli - Vice President of Investor RelationsBill...
November 9, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
November 9, 2022

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.05
Daily high3.08
Daily low2.94
Daily Volume761K
All-time high30.94
1y analyst estimate5.40
Beta2.16
EPS (TTM)-0.46
Dividend per share-
Ex-div date-
Next earnings date3 May 2023

Downside potential

Loading...
Downside potential data
ABUSS&P500
Current price drop from All-time high-90.47%-17.92%
Highest price drop-97.19%-56.47%
Date of highest drop9 Oct 20199 Mar 2009
Avg drop from high-71.84%-11.51%
Avg time to new high115 days13 days
Max time to new high2275 days1805 days
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with this event.
November 7, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
November 2, 2022

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABUS (Arbutus Biopharma Corp) company logo
Marketcap
464.63M
Marketcap category
Small-cap
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Employees
85
Investor relations
-
SEC filings
CEO
William H. Collier
Country
USA
City
Warminster
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Arbutus Biopharma stock seems to be building a floor at current trading levels. Read more for a full investment analysis of ABUS stock.
September 12, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
August 30, 2022

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
Arbutus Biopharma Corporation (NASDAQ:NASDAQ:ABUS) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ETCompany ParticipantsLisa Caperelli - Vice President of Investor RelationsBill...
August 4, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
August 4, 2022

iO Charts is a Seeking Alpha partner

COMPANY NEWS
All newsPress releases
A roundup of recent Philadelphia-area life sciences news, including medical device makers Strados Labs and Helius Medical enter into product deals.
March 24, 2023
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
March 19, 2023
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical compan...
March 16, 2023
Antiviral potency, selectivity and favorable PK support further development of AB-343 as potential ritonavir-free oral treatment for COVID-19 and other human coronaviruses WARMINSTER, Pa., March 14, 2...
March 14, 2023
Despite the backing of the U.S. government, Moderna Inc on Friday failed to persuade a federal judge it should not have to face a patent lawsuit over its COVID-19 vaccine and that the United States sh...
March 10, 2023
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation Fourth Quarte...
March 6, 2023
Q4 2022 Arbutus Biopharma Corp Earnings Call
March 3, 2023
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
March 2, 2023
Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD...
March 2, 2023
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
February 16, 2023
Next page
Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
August 3, 2022

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from Arbutus Biopharma Corporation (ABUS) stock at Seeking Alpha.
July 20, 2022

iO Charts is a Seeking Alpha partner